NeuroSense Total Liab from 2010 to 2024

NRSNW Stock  USD 0.25  0.13  34.21%   
NeuroSense Therapeutics Total Liabilities yearly trend continues to be fairly stable with very little volatility. Total Liabilities is likely to outpace its year average in 2024. Total Liabilities is the total amount of all liabilities that NeuroSense Therapeutics Ltd has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2010-12-31
Previous Quarter
M
Current Value
5.3 M
Quarterly Volatility
1.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 186.9 K, Depreciation And Amortization of 101.8 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
  
Check out the analysis of NeuroSense Therapeutics Correlation against competitors.
For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

Latest NeuroSense Therapeutics' Total Liab Growth Pattern

Below is the plot of the Total Liab of NeuroSense Therapeutics Ltd over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. NeuroSense Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuroSense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

NeuroSense Total Liab Regression Statistics

Arithmetic Mean1,023,900
Geometric Mean133,742
Coefficient Of Variation181.17
Mean Deviation1,436,387
Median37,000
Standard Deviation1,855,002
Sample Variance3.4T
Range5.3M
R-Value0.75
Mean Square Error1.6T
R-Squared0.56
Significance0
Slope310,741
Total Sum of Squares48.2T

NeuroSense Total Liab History

20245.3 M
2023M
20222.1 M
20212.4 M
2020120 K

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total LiabilitiesM5.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.